Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 07, 2025
Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: April 25, 2025
Long-acting HIV Treatments: Study Design, Logistics, and Access.
Journal: Open forum infectious diseases
Published: April 05, 2024
Antiretrovirals and Weight Change: Weighing the Evidence.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 05, 2023
Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: August 08, 2020
HIV and Orthopaedics: Musculoskeletal Manifestations and Outcomes.
Journal: The Journal of bone and joint surgery. American volume
Published: May 06, 2016
Predictors of short-term diabetes remission after laparoscopic Roux-en-Y gastric bypass.
Journal: Obesity surgery
Published: November 02, 2014
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 31, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.
Journal: AIDS research and human retroviruses
Published: January 29, 2013
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
Journal: International journal of STD & AIDS
Published: March 11, 2010
Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients.
Journal: AIDS patient care and STDs
Published: May 24, 2007
Antiretroviral treatment considerations in Latino patients.
Journal: AIDS patient care and STDs
Published: July 02, 2005
Last Updated: 09/26/2026